Zanamivir (hydrate)(5:1) 

Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC₅₀ values of 0.95 nM and 2.7 nM for influenza A and B, respectively^[1].

IC₅₀: 0.95 nM (Influenza A); 2.7 nM (Influenza B)^[1]

Zanamivir has a poor bioavailability in oral administration, with only 4-17% of the agent. Oral delivery of Zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

335.91

C₁₂H_20.4N₄O_7.2

171094-50-1

NC(N[C@@H]1[C@H]([C@@]([H])(OC(C(O)=O)=C1)[C@@H]([C@@H](CO)O)O)NC(C)=O)=N.[0.2 H2O]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8.  [Content Brief]

  [2]. McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16.  [Content Brief]

  [3]. Shanmugam S, et al. Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul). 2013 Mar;21(2):161-9.  [Content Brief]